RSV vaccine for pregnant women inches closer to approval with FDA committee recommendation
Fox News
The FDA voted to recommend approval of Pfizer’s RSV vaccine for pregnant women, bringing it one step closer to becoming the first maternal immunization to protect infants from respiratory syncytial virus.
The committee also voted 10-4 on the safety of the vaccine. "Giving it to pregnant women gives passive protection to the fetus, which then carries over to early infancy." Melissa Rudy is health editor and a member of the lifestyle team at Fox News Digital.
"We are encouraged by the outcome of today’s VRBPAC meeting, as it is a critical step forward in the scientific community’s long-sought-after goal to help prevent RSV disease in infants during their most vulnerable first six months of life," said Annaliesa Anderson, PhD, Pfizer’s senior vice president and chief scientific officer of vaccine research and development, in a media statement.